Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS >=550%, treatment-naive NSCLC

被引：0

作者：

Satouchi, Miyako ^{[1
]}

Hotta, Katsuyuki ^{[2
]}

Nosaki, Kaname ^{[3
]}

Takahashi, Toshiaki ^{[4
]}

Nakagawa, Kazuhiko ^{[5
]}

Aoe, Keisuke ^{[6
]}

Noguchi, Kazuo ^{[7
]}

Shimamoto, Takashi ^{[7
]}

Rangwala, Reshma ^{[7
]}

Brahmer, Julie ^{[8
]}

机构：

[1] Okayama Univ, Hyogo Canc Ctr, Dept Thorac Oncol, Okayama, Japan

[2] Okayama Univ, Dept Resp Med, Okayama, Japan

[3] Kindai Univ, Dept Thorac Oncol, Kyushu Natl Canc Ctr, Higashiosaka, Osaka, Japan

[4] Kindai Univ, Shizuoka Canc Ctr, Dept Thorac Oncol, Higashiosaka, Osaka, Japan

[5] Kindai Univ, Dept Med Oncol, Higashiosaka, Osaka, Japan

[6] Yamaguchi Ube Med Ctr, Dept Med Oncol, Ube, Yamaguchi, Japan

[7] MSD KK, Tokyo, Japan

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS-3

引用

页码：73 / 73

页数：1

Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS &gt;=550%, treatment-naive NSCLC